Prosetta's Clinical & Scientific Advisory Board
Ian Lipkin, MD
Ian Lipkin, MD, is the John Snow Professor of Epidemiology, Professor of Neurology and Pathology and Director of the Center for Infection and Immunity at Columbia University. He is also Director of the Northeast Biodefense Center and the WHO Collaborating Centre on Diagnostics, Surveillance and Immunotherapeutics for Emerging Infectious and Zoonotic Diseases. A graduate of Sarah Lawrence College, he obtained his MD at Rush Medical College, Medicine Residency at the University of Washington, Neurology Residency at the University of California San Francisco, and Fellowship in Neurovirology and Neuroscience at The Scripps Research Institute. Lipkin is an expert in pathogen surveillance and discovery, diagnostics and microbial pathogenesis.
Jairam Lingappa, MD, PhD
Dr. Jairam R. Lingappa received his PhD in Biophysics from Harvard University in 1987 and an MD from the University of California, San Francisco in 1991, completing training in Pediatrics and Pediatric Infectious Diseases at the University of Washington, and field epidemiology at the Centers for Disease Control and Prevention (CDC). In 2004 he joined the University of Washington faculty as the Medical Director for a large randomized clinical trial to assess the efficacy of genital herpes (HSV-2) suppression with daily acyclovir to reduce the risk of HIV-1 transmission and HIV-1 disease progression among African heterosexual HIV-1 serodiscordant couples (one partner HIV-1 infected and one HIV-1 uninfected). Dr. Lingappa is now an Associate Professor in the Departments of Global Health, Medicine and Pediatrics, and Associate Director of the International Clinical Research Center (ICRC) at the University of Washington. His current focus is building collaborative studies to better understand host molecular determinants of susceptibility to and disease outcomes from HIV-1.
Robert Prust, MD
Dr. Prust received his B.S degree from the University of Michigan in 1976, M.S. degree in Biochemistry from Wayne State University in 1981, and M.D. degree from Wayne State University in 1982, followed by a residency and fellowship in Radiation Oncology at the University of Michigan. Since 1998, Robert has pursued a career in the clinical practice of Radiation Oncology at Munson Medical Center in Traverse City, Michigan. He is an active member in the American Society for Radiation Oncology and the American Board of Radiology.
Dale Bredesen, MD
Dr. Dale Bredesen is internationally recognized as an expert in the mechanisms of neurodegenerative diseases such as Alzheimer’s disease. His research focuses on the mechanisms of cell death in the nervous system and has led to a new approach to Alzheimer’s disease therapeutics. Dr. Bredesen earned his undergraduate degree at Caltech, his MD at Duke University, and completed his neurology residency at UCSF. He was an NIH Fellow in the laboratory of Nobel Laureate Stanley Prusiner. In 1989 he joined the faculty at UCLA, where he was awarded the Elizabeth R. and Thomas E. Plott Chair. In 1994, he was recruited to the Burnham Institute to direct the Program on Aging, and then in 1998 became the Founding President and CEO of the Buck Institute for Research on Aging, the nation’s only independent institute devoted to research on aging and age- associated disease. He has held faculty positions at UCSF, UCLA and the University of California, San Diego. He recently completed a term as a member of the National Advisory Council on Aging. The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 200 research papers. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease. His group has developed a new approach to the treatment of Alzheimer’s disease, and this approach has led to the first description of reversal of symptoms in patients with MCI and early Alzheimer’s disease, with the MEND protocol.